Literature DB >> 3124732

Disk diffusion susceptibility testing of Branhamella catarrhalis with ampicillin and seven other antimicrobial agents.

G V Doern1, T Tubert.   

Abstract

A total of 74 clinical isolates of Branhamella catarrhalis were characterized with respect to their ampicillin, amoxicillin-clavulanate, cephalothin, cefaclor, erythromycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole MICs and zones of inhibition. Disk diffusion tests were performed according to the guidelines of the National Committee for Clinical Laboratory Standards with two different media (Mueller-Hinton agar and chocolate Mueller-Hinton agar) and plates incubated under two atmospheric conditions (ambient air and 5 to 7% CO2). Optimum disk diffusion test results were obtained with Mueller-Hinton agar plates incubated in ambient air with all eight antimicrobial agents. On the basis of comparisons of MICs versus zones of inhibition, the following zone diameter interpretive criteria were defined for testing B. catarrhalis with disks containing 10 micrograms of ampicillin: greater than or equal to 38 mm, susceptible; 20 to 37 mm, moderately susceptible; less than or equal to 19 mm, resistant. The respective MIC correlates were less than or equal to 0.06, 0.125 to 0.5, and greater than or equal to 1.0 micrograms/ml. Because of the absence of frankly resistant test organisms, it was not possible to make definitive recommendations pertaining to disk diffusion tests with amoxicillin-clavulanate, cephalothin, cefaclor, erythromycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole. Evidence is presented, however, which suggests that the current National Committee for Clinical Laboratory Standards disk diffusion interpretive criteria for nonfastidious bacteria can be applied to B. catarrhalis, at least as they pertain to the susceptible category with cephalothin, amoxicillin-clavulanate, erythromycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole. With cefaclor, a zone diameter of greater than or equal to 21 mm was determined to adequately define the susceptible category.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124732      PMCID: PMC174982          DOI: 10.1128/AAC.31.10.1519

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis.

Authors:  E E Stobberingh; H J van Eck; A W Houben; C P van Boven
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Identification and antimicrobial susceptibility testing of Branhamella catarrhalis in United States laboratories, 1983-1985.

Authors:  R N Jones; H M Sommers
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 3.  Branhamella catarrhalis--an emerging human pathogen.

Authors:  G V Doern
Journal:  Diagn Microbiol Infect Dis       Date:  1986-03       Impact factor: 2.803

4.  In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

Authors:  S Alvarez; M Jones; S Holtsclaw-Berk; J Guarderas; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

6.  Branhamella catarrhalis respiratory infections in The Netherlands.

Authors:  F P Maesen; B I Davies
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections.

Authors:  M A Calder; M J Croughan; D T McLeod; F Ahmad
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Sensitivity of Branhamella catarrhalis to oral antibiotics.

Authors:  I Kallings
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in The Netherlands.

Authors:  B I Davies; F P Maesen
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Antibiotic sensitivity of Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes and Branhamella catarrhalis isolated from upper respiratory tract infections in Sweden.

Authors:  I Kallings; S Bengtsson; P Christensen; S E Holm; L Lind; M Kalin
Journal:  Scand J Infect Dis Suppl       Date:  1983
View more
  9 in total

Review 1.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

Authors:  G V Doern; T A Tubert
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

3.  Clinical features fail to distinguish respiratory infections caused by Branhamella catarrhalis from those caused by Haemophilus influenzae.

Authors:  K R Forward
Journal:  Can J Infect Dis       Date:  1992-01

4.  In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.

Authors:  J P Bryan; C Waters; J Sheffield; K F Wagner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

5.  In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.

Authors:  G V Doern; R Vautour; D Parker; T Tubert; B Torres
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

6.  Colonization and infection with Moraxella catarrhalis in childhood.

Authors:  R Berner; R F Schumacher; M Brandis; J Forster
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

7.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

8.  Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards.

Authors:  P C Kibsey; R P Rennie; J E Rushton
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

9.  Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).

Authors:  G V Doern; R N Jones; M A Pfaller; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.